SynthesisScientific reports2016
Prognostic significance of neutrophil-to-lymphocyte ratio in prostate cancer: evidence from 16,266 patients.
Synthesis in Scientific reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 81 papers, 7 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
81 citing papers in PubMed, 7 syntheses or guidelines pooled it.
- Pooled it
- Pooled it
- The prognostic value of neutrophil-to-lymphocyte ratio in cholangiocarcinoma: a systematic review and meta-analysis.Scientific reports · 2022Pooled it
- Revealing the prognostic landscape of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in metastatic castration-resistant prostate cancer patients treated with abiraterone or enzalutamide: a meta-analysis.Prostate cancer and prostatic diseases · 2020Pooled it
- Pooled it
- Prognostic Role of Neutrophil to Lymphocyte Ratio in Ovarian Cancer: A Meta-Analysis.Technology in cancer research & treatment · 2018Pooled it
- Prognostic significance of neutrophil-to-lymphocyte ratio in cervical cancer: A systematic review and meta-analysis of observational studies.Oncotarget · 2017Pooled it
- Trial
- Prognostic value of the neutrophil/lymphocyte ratio in enteropancreatic neuroendocrine tumors.Anti-cancer drugs · 2020Trial
- Safety, efficacy and survival of patients with primary malignant brain tumours (PMBT) in phase I (Ph1) trials: the 12-year Royal Marsden experience.Journal of neuro-oncology · 2018Trial
- Vitamin D and adverse pathologic features in patients undergoing radical prostatectomy in the contemporary magnetic resonance imaging-guided management era.BJUI compass · 2026Article
- C-reactive protein-albumin-lymphocyte index predicts biochemical recurrence in prostate cancer.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2026Article
- Search for prognostic markers of mortality in inpatients receiving palliative chemotherapy.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Observational
- Article
- The low-grade Inflammation Score (INFLA-Score) as a predictor of overall survival in prostate cancer: a UK biobank cohort study.BMC urology · 2026Article
- Low-dose radiotherapy synergizes with PD-1 blockade to achieve durable survival in advanced NSCLC through antitumor neutrophil programming.Signal transduction and targeted therapy · 2026Article
- Prognostic effect of systemic inflammation in patients undergoing cytoreductive surgery and hyperthermic intrathoracic chemotherapy.Turk gogus kalp damar cerrahisi dergisi · 2026Article
- Prognostic Role of Inflammatory Biomarkers in Gastrointestinal Neuroendocrine Neoplasms: A Cross-Sectional Study.Health science reports · 2025Article
- Hematological parameters as predictors of prostate cancer: A study based on multivariable and bidirectional Mendelian randomization.Medicine · 2025Article
- The immune landscape of systemic inflammation in prostate cancer.Cancer biology & medicine · 2025Review
21 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study was aimed to investigate the prognostic value of neutrophil-to-lymphocyte ratio (NLR) in patients with prostate cancer (PCa). A meta-analysis including 14 publications (15 cohorts) with 16,266 patients was performed to evaluate the association between NLR and overall survival (OS), progression-free survival (PFS)/recurrence-free survival (RFS) in PCa using hazard ratio (HR) and 95% confidence intervals (95% CI). The combining data showed that increased NLR predict poor OS (HR = 1.38, 95%CI: 1.22-1.56) and PFS/RFS (HR = 1.24, 95%CI 1.05-1.46) in PCa. Stratified analysis by PCa type, sample size, ethnicity and NLR cut-off value revealed that NLR showed consistent prognostic value in metastatic castration-resistant prostate cancer (mCRPC) patients and predict poor PFS/RFS in Asians, but not in Caucasians. These statistical data suggested that increased NLR could predict poor prognosis in patients with PCa.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.